Immunotherapy with HDAC inhibitor against malignant glioma
| Project/Area Number |
23592137
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
SATO Hidemitsu 横浜市立大学, 医学(系)研究科(研究院), 客員研究員 (70363801)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KANNO Hiroshi 横浜市立大学, 医学研究科, 客員准教授 (40244496)
|
|---|
| Project Period (FY) |
2011-04-28 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | gliioblastoma / immunotherapy / HDAC inhibitor / MGMT promotor / temozolomide / valproate / glioblastoma / glioma / HDAC inhibitor / MGMT / valproic acid / MGMTpromotor / pyrosequence / 免疫療法 / グリオーマ / HDAC阻害作用 / バルプロ酸 / グリオーマ特異抗原 / MHC / IDH mutation |
|---|
| Outline of Final Research Achievements |
Valproate(VPA) is an anti-epileptic agent with abilities of a histone deacetylase inhibitor (HDACi) which enhances immune response. Recent studies suggest that VPA is associated with improved survival in glioblastomas (GBMs). We examined the immunological mechanisms of VPA against GBMs. VPA emphasized the cytotoxic activity against GBM cell line by stronger expression of immune related surface markers like major histocompatibility complex (MHC) class I resulted in enhanced expression of glioma antigens.
Moreover, we examined the influence of VPA against the methylation of O6-methylguanin-DNA-methyltransferase (MGMT) promotor by pyrosequence analysis. In our study, VPA did not have adverse influence of temozolomide resistant activity in GBMs. Taken together, we suggested that VPA might be recommended to use for combined therapy of temozolomide and immunotherapy against GBMs.
|
Report
(6 results)
Research Products
(7 results)
